Compare Southern Copper Corp (SCCO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southern Copper Corp vs Summit Therapeutics Inc — how do they compare? Southern Copper Corp trades at $209 (market cap $176.10B), while Summit Therapeutics Inc trades at $17.52 (market cap $13.79B). The key difference: Southern Copper Corp is far larger — about 12.8× Summit Therapeutics Inc's market cap, and Southern Copper Corp pays a 2.11% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SCCO | SMMT | |
|---|---|---|
Market Cap | $176.10B | $13.79B |
Sector | Basic Materials | Health |
52-Week High | $219.70 | $26.38 |
52-Week Low | $102.10 | $12.43 |
Enterprise Value | $177.39B | $13.11B |
Dividend Yield | 2.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southern Copper (SCCO) trades at $208.56, up 4.93% with strong bullish technical signals and positive earnings momentum. The company demonstrates robust fundamentals with 2025 revenue of $13.42B, net income margin of 35.87%, and consistent earnings beats. Recent news highlights copper's role in AI infrastructure demand, with SCCO benefiting from rising metal prices and a $20.5B investment plan for production growth.
SCCO presents growth potential from copper demand trends but trades at premium valuations (P/E 31.29) above analyst consensus target of $154.58. Key risks include production declines and execution challenges on expansion projects. Institutional buying activity suggests confidence in long-term prospects despite mixed analyst ratings.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
